Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Targeting WT1 peptides for TCR-based AML therapy

Chiara Bonini, MD, Vita-Salute San Raffaele University & IRCCS San Raffaele Institute, Milan, Italy, describes research into the evaluation of Wilms’ tumor antigen 1 (WT1) as a candidate peptide for T cell receptor (TCR)-based cancer immunotherapies. Dr Bonini describes the screening of healthy donors for the presence of WT1-specific T cells and it was found that T cells specific for WT1 were present in the majority of donors tested. A high-avidity WT1-specific TCR that recognizes human leukocyte antigen class II (HLA-II) peptides was then selected using a funnel approach and ongoing research aims to evaluate the clinical potential of T cells engineered to express this TCR in the treatment of AML. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.